title: [A case responding to weekly paclitaxel therapy as second-line chemotherapy for gastric cancer previously treated with TS-1].
abstract: A 58-year-old male patient with the recurrence of para-aortic lymphnodes after TS-1 treatment was treated by a weekly infusion of paclitaxel as second-line chemotherapy. Paclitaxel was administered at a weekly dose of 70 mg/m2/day for three weeks followed by a one week interval. After 2 courses, the tumor was reduced, and the reduction was judged as PR. Moreover, after 5 courses, the tumor was more remarkably reduced and the reduction was judged as CR. The grade 2 leukopenia, neutropenia, and grade 1 alopecia were observed as adverse events. Recently, we treated 11 patients of advanced or recurrent gastric cancers with measurable lesions, using the weekly paclitaxel therapy after TS-1 treatment. The response rate was 36.4%. The median duration of PR was 130 days. Therefore, a weekly paclitaxel regimen was considered to be one of the promising regimens for advanced or recurrent gastric cancer as the second-line chemotherapy after TS-1 treatment.
authors.affiliation: Dept. of Surgery, Sakai City Hospital.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Imamura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Furukawa
authors.forename: Kentaro
authors.initials: K
authors.lastname: Kishi
authors.forename: Masayuki
authors.initials: M
authors.lastname: Tatsuta
authors.forename: Seizo
authors.initials: S
authors.lastname: Masutani
authors.forename: Mutsumi
authors.initials: M
authors.lastname: Fukunaga
authors.forename: Takahiro
authors.initials: T
authors.lastname: Nakayama
authors.forename: Junzo
authors.initials: J
authors.lastname: Shimizu
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Takemoto
authors.forename: Tomono
authors.initials: T
authors.lastname: Kishimoto
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kato
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Makoto
authors.initials: M
authors.lastname: Fujishima
authors.forename: Takatoshi
authors.initials: T
authors.lastname: Kawasaki
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004338:Drug Combinations; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000627:therapeutic use*; D017239:Paclitaxel / Q000008:administration & dosage*; D011725:Pyridines / Q000627:therapeutic use*; D005641:Tegafur / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D017239:Paclitaxel